Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective case series.
BACKGROUND
Intralesional methotrexate (IL-MTX) is an effective treatment for keratoacanthoma.


OBJECTIVE
We sought to determine the response rates and adverse events in KA treated with intralesional methotrexate.


METHODS
All cases of KA treated with intralesional methotrexate at our institutions from 2001 to 2009 were systematically reviewed.


RESULTS
Forty-six cases of KA treated with IL-MTX were identified. A complete resolution was achieved in 74% of patients, requiring an average of 1.8 injection sessions, for a mean total dose of 10 mg. Adverse events did not occur.


CONCLUSIONS
The follow-up period was short, and there was no histologic confirmation of the initial diagnosis.


CONCLUSIONS
IL-MTX is an effective and well-tolerated alternative to surgery for the treatment of KA.
Department of Dermatology, Centre Hospitalier Universitaire de Québec, Quebec City, QC.
Nicolas
N
Aubut
Jimmy
J
Alain
Joël
J
Claveau
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate